M&A · Healthcare · Pharmaceutical Preparations
ArchiMed to acquire Esperion Therapeutics, Inc.
Announced May 1, 2026 · Closed Jul 13, 2026
Deal value$812MEV $741M
Premium58.0%To unaffected price
EV / Adj. EBITDA10.5x1.8x EV / Revenue
ConsiderationAll cash$3.16 per share
Transaction
- Acquirer
- ArchiMed
- Target
- Esperion Therapeutics, Inc. (ESPR)
- Buyer type
- Private equity
- Offer price per share
- $3.16
- Enterprise value
- $741M
- Status
- Closed Jul 13, 2026
Deal protections
- Break fee (target pays)
- $34.2M · 4.2%
- Reverse fee (buyer pays)
- $68.3M · 8.4%
- Go-shop
- —
- Financing
- No financing condition
Advisors
- To the acquirer
- Moelis
- To the target
- Centerview
- Centerview fee
- $37.5M
Sector context · Healthcare
- Comparable deals
- 100 in the prior 24 months
- Premium
- 58.0% vs. 50.0% sector median
- EV / Adj. EBITDA
- 10.5x vs. 13.4x sector median
- Break fee
- 4.2% vs. 3.3% sector median
Timeline
- AnnouncedMay 1, 2026
- Proxy filedMay 29, 2026
- Definitive proxyJun 8, 2026
- Shareholder voteJul 8, 2026
- ClosedJul 13, 2026
Valuation · fairness opinions
Trading comparables$1.58$3.52
Precedent transactions$2.39$4.33
Discounted cash flow$2.79$3.13
Analyst price targets$2.00$16.00
Premiums paid$2.70$3.60
Offer $3.16
Implied value per Esperion Therapeutics, Inc. share by analysis, from Centerview.